** Brokerage Leerink Partners raises PT on drugmaker Gilead Sciences GILD.O to $114 from $105

** Brokerage says it does not anticipate any "major top- or bottom-line surprises" in GILD's earnings, ahead of its Q2 results likely to be reported in early August

** Maintains "outperform" rating

** The new price target represents a 3.97% upside to the stock's last close

** Aside from earnings, brokerage says "the central focus will be on two recent HIV PrEP and treatment pipeline developments"

** Brokerage says GILD's recently approved twice-yearly injectable HIV PrEP, Yeztugo, can quickly and widely become available, considering its lower price compared to its once-daily PrEP drug, Descovy, and its efficacy even though unclear guidelines after U.S. top court ruling on preventative coverage and CMS

** Twenty of 30 brokerages rate the stock "buy" or higher, 10 "hold"; their median PT is $118.50 - data compiled by LSEG

** Up to last close, stock up 18.7% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))